• Angiotensin I/II (1-5): RAS Workflow Guide

  2026-09-21

  Angiotensin I/II (1-5), the Asp-Arg-Val-Tyr-Ile peptide fragment, provides a defined reagent for renin-angiotensin system research involving blood pressure regulation, renal physiology, and aldosterone release stimulation. This guide covers solvent selection, storage, controls, and troubleshooting; the peptide should not be generalized to unrelated signaling assays or used as evidence of clinical efficacy.

• Peptidisc-Assisted Nanobody Multimerization

  2026-09-21

  This preprint presents peptidisc-assisted hydrophobic clustering as a strategy for assembling nanobodies into soluble multimeric, bispecific, and autofluorescent proteins. By coupling nanobodies to transmembrane segments and stabilizing the resulting hydrophobic associations with a peptidisc, the authors report enhanced avidity and a flexible alternative to tandem fusion, scaffold-based assembly, and chemical cross-linking.

• Biotin-tyramide for Spatial Assay Design

  2026-09-20

  Biotin-tyramide enables enzyme-mediated signal amplification when spatial localization matters more than bulk abundance. This article connects HRP-based TSA with APEX-RNA-MS to clarify assay selection, controls, and practical workflow design.

• Angiotensin I/II (1-5): Protocol and QC Guide

  2026-09-19

  Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for controlled renin-angiotensin system research involving blood pressure regulation and aldosterone signaling. It is intended for cardiovascular and renal workflows, not unrelated peptide studies, and its water insolubility requires deliberate solvent selection and vehicle controls.

• Gasdermin C Drives Stemness and Immune Evasion in PDAC

  2026-09-18

  A 2024 Advanced Science study identifies Gasdermin C (GSDMC) as a nuclear regulator of pancreatic ductal adenocarcinoma rather than solely a pyroptosis-associated pore-forming protein. The work links ADAM17-dependent GSDMC cleavage to stemness, metastasis, and immune evasion, while showing that GSDMC disruption can improve responses to KRASG12D inhibition and PD-1 checkpoint blockade in preclinical models.

• From HATU Coupling to Translational Inhibitors

  2026-09-18

  A mechanistic and strategic guide to using HATU in peptide synthesis chemistry, informed by structure-based inhibitor discovery against IRAP and ERAP1.

• Dronedarone (Multaq) Research Workflows

  2026-09-17

  Build reproducible Dronedarone (Multaq) workflows for automated electrophysiology, atrial fibrillation treatment research, and cardiac arrhythmia pharmacology. The key differentiator is its value as a multi-ion-channel comparator that helps separate direct KCa2 channel effects from broader antiarrhythmic pharmacology.

• CFTRinh-172 Workflow for CFTR Inhibition

  2026-09-17

  CFTRinh-172 gives researchers rapid, reversible control of CFTR chloride conductance without directly targeting cAMP production or membrane trafficking. This article connects acute transport assays with surface-abundance measurements, epithelial disease models, and troubleshooting strategies for more interpretable cystic fibrosis research.

• PPP1R3G/PP1γ Control of RIPK1 Cell Death

  2026-09-16

  The reference study identifies PPP1R3G as a regulatory subunit that recruits PP1γ to TNFR1 complex I, removes inhibitory RIPK1 phosphorylation, and enables RIPK1-dependent apoptosis and type I necroptosis. Its genetic, biochemical, and in vivo evidence establishes phosphatase-controlled RIPK1 activation as a key connection between inflammatory signaling and regulated cell death.

• MRSA EVs Drive OSCC Proliferation via IL-8

  2026-09-16

  This study shows that extracellular vesicles released by methicillin-resistant Staphylococcus aureus can enter oral squamous cell carcinoma cells and stimulate tumor growth more strongly than vesicles from methicillin-susceptible S. aureus. Its mechanistic contribution is the identification of an EV–ERK/c-Jun–IL-8–CXCR1 signaling axis, supported by IL-8 knockout and CXCR1-blockade experiments in an ectopic tumor model.

• Ivermectin, GSDMC, and Translational Rigor

  2026-09-15

  A translational perspective on Ivermectin as a broad-spectrum anti-parasitic and on GSDMC biology in pancreatic cancer, separating established parasitology utility from hypothesis-generating oncology research.

• CCR7–Notch1 Crosstalk Promotes Mammary Cancer Stemness

  2026-09-15

  Boyle et al. identify a functional interaction between CCR7 and Notch1 in primary MMTV-PyMT mammary tumor cells, linking chemokine signaling to cancer stem-like behavior. Their genetic and pathway-blockade experiments suggest that simultaneous disruption of both axes may be more informative than studying either pathway in isolation, although translation beyond this mouse model remains unresolved.

• Pretomanid Targets Both Terminal Oxidases in Tuberculosis

  2026-09-14

  The reference study identifies the cytochrome bcc:aa3 and cytochrome bd terminal oxidases as coordinated respiratory targets of pretomanid in Mycobacterium tuberculosis. Its combination data show that pairing pretomanid with Q203, with or without ND-011992, can strengthen killing across replicating and antibiotic-tolerant states while limiting resistance emergence.

• Salvianolic acid B in Pulmonary Fibrosis Research

  2026-09-14

  Salvianolic acid B, also called Dan Shen Suan B, gives fibrosis researchers a practical way to connect LH2 expression with collagen cross-linking, matrix stiffness, and tissue remodeling. This guide translates the published mechanism into concentration-response, cell-based, and orthogonal ECM workflows while addressing solubility, assay interference, and interpretation limits.

• Angiotensin I/II (1-5): RAS Workflow Guide

  2026-09-13

  This guide explains how to handle Angiotensin I/II (1-5), a defined Asp-Arg-Val-Tyr-Ile peptide fragment for controlled renin-angiotensin system research. It is suited to cardiovascular, renal, blood pressure, and aldosterone workflows, but its poor water solubility and fragment-specific scope limit use in unrelated assays.

8645 records 1/577 page Next 12345 下5页 Last page